

PRESS RELEASE



CONTACT:

InVasc Therapeutics, Inc.
William D. Johnston, Ph.D.
Chief Executive Officer
(678) 736-5903
bjohnston@invasctherapeutics.com

FOR IMMEDIATE RELEASE

INVASC THERAPEUTICS, INC. AWARDED TWO PHASE 1 SBIR GRANTS

ATLANTA, Georgia – May 19, 2010 – InVasc Therapeutics, Inc. today announced that it has been awarded two Small Business Innovations Research (SBIR) Phase 1 grants by the National Institutes of Health. One grant is to continue research and development of small molecule drugs for the prevention and treatment of hypertension and stroke based on derivatives of alpha lipoic acid. The second grant is to advance the discovery and development of inhibitors of myeloperoxidase for use in treating or preventing acute vascular or inflammatory events. The aggregate funding from these two Phase 1 grants is nearly \$400,000.

“We are very pleased with the acknowledgement of our foundational work in these critical clinical areas and NIH’s recognition of our research strength by awarding these two grants,” stated William Johnston, Ph.D., CEO of InVasc. “These grants will facilitate the continued development of several early stage drug candidates in our pipeline and support our objective of being positioned to file an IND application on an annual basis for several years.”

“These grants recognize InVasc’s unique approach of derivatizing naturally occurring compounds to address the critical needs associated with cardiovascular diseases and diabetes,” indicated Bobby V. Khan, M.D., Ph.D., a founder, director and chair of InVasc’s Scientific Advisory Board. “Preliminary candidates have shown distinct activity in cellular assays for improved vascular function and favorable effects in regulating enzymes linked to cardiovascular tissue damage.”

About InVasc

InVasc Therapeutics, Inc., headquartered in Tucker, Georgia, is a biopharmaceutical company developing drugs to mitigate risks associated with cardiometabolic diseases. Cardiovascular and metabolic diseases such as diabetes, hypertension, stroke and dyslipidemia are the leading causes of morbidity and mortality worldwide. The Company plans to file an IND later this year for its INV-144 drug aimed at reducing proteinuria in hypertensive diabetic patients. In a human clinical trial, INV-141, a sister compound, demonstrated statistical significance in the reduction of proteinuria in the same patient population.

###